Pacifico A, Wheelan K R, Nasir N, Wells P J, Doyle T K, Johnson S A, Henry P D
Texas Arrhythmia Institute, Houston 77030, USA.
Circulation. 1997 Feb 18;95(4):946-50. doi: 10.1161/01.cir.95.4.946.
Implantable cardioverter-defibrillators (ICDs) with intravenous electrode systems and downsized generators can be implanted by use of operative techniques similar to those employed for the insertion of permanent pacemakers. However, the safety, efficacy, and long-term follow-up of simplified implantation procedures remain to be evaluated. This report is a prospective long-term evaluation of nonselected patients receiving ICDs in the prepectoral subfascial position under conscious sedation.
Clinical characteristics of the 231 consecutive patients included a mean age of 63 years, a male-to-female ratio of 6.4, a left ventricular ejection fraction of 0.34, a mild-to-moderate heart failure in 91%, coronary artery disease in 84%, and a history of aborted sudden cardiac death or refractory ventricular tachyarrhythmias. Insertion of transvenous leads and prepectoral subfascial ICD implantation were performed in electrophysiology laboratories under local anesthesia and conscious sedation with intravenous midazolam and propofol. Successful implantation in all patients (operation time, 80 +/- 32 minutes, mean +/- SD) irrespective of body size and skin thickness was free of major complications, including need for emergency intubation. After surgery, 1 pocket hematoma, 1 seroma, and 1 pneumothorax required treatment. There was no operative or first-month mortality. During long-term follow-up averaging 453 +/- 296 days, six leads required repositioning, but pocket erosions or infections did not occur. First-year total survival was 97%.
Implantation under conscious sedation of ICDs in the prepectoral subfascial position is a safe and effective procedure with low operative and postoperative morbidity and favorable long-term outcome.
带有静脉电极系统和小型化发生器的植入式心脏复律除颤器(ICD)可通过与永久性起搏器植入所用技术相似的手术技术进行植入。然而,简化植入程序的安全性、有效性及长期随访情况仍有待评估。本报告是对在清醒镇静下于胸前筋膜下位置接受ICD植入的非选择性患者进行的前瞻性长期评估。
231例连续患者的临床特征包括平均年龄63岁,男女比例为6.4,左心室射血分数为0.34,91%有轻至中度心力衰竭,84%有冠状动脉疾病,以及有心源性猝死未遂或难治性室性快速心律失常病史。在局部麻醉和静脉注射咪达唑仑及丙泊酚的清醒镇静下,于电生理实验室进行经静脉导线插入及胸前筋膜下ICD植入。所有患者均成功植入(手术时间为80±32分钟,平均±标准差),无论体型和皮肤厚度如何,均无包括紧急插管需求在内的重大并发症。术后,1例出现皮下血肿、1例出现血清肿、1例出现气胸,均需治疗。无手术或首个月死亡情况。在平均453±296天的长期随访期间,6根导线需要重新定位,但未发生囊袋侵蚀或感染。第一年总生存率为97%。
在清醒镇静下于胸前筋膜下位置植入ICD是一种安全有效的手术,手术及术后发病率低,长期预后良好。